View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCowen 과거 순이익 실적과거 기준 점검 2/6핵심 정보49.53%순이익 성장률49.54%주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률19.20%자기자본이익률4.98%순이익률5.45%최근 순이익 업데이트31 Dec 2022최근 과거 실적 업데이트공고 • Feb 10Cowen Inc. to Report Q4, 2022 Results on Feb 17, 2023Cowen Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 17, 2023모든 업데이트 보기Recent updates공고 • Feb 10Cowen Inc. to Report Q4, 2022 Results on Feb 17, 2023Cowen Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 17, 2023공고 • Jan 13Cowen Inc. Announces the Demise of Jack H. Nusbaum, DirectorCowen Inc. announced with great sadness that Director Jack H. Nusbaum passed away unexpectedly on January 11, 2021. Mr. Nusbaum has served as a member of Cowen’s Board since November 2009. He has been an advisor and friend to members of the Company’s leadership for over 30 years. Mr. Nusbaum was also a Senior Partner of the New York law firm of Willkie Farr & Gallagher LLP, serving as the firm’s Chairman from 1987 through 2009 and a partner in that firm for fifty years.공고 • Jan 06Joram Siegel Joins Cowen as Head of Fixed Income Outsourced TradingCowen Inc. announced that Joram Siegel has joined its Outsourced Trading division as Managing Director, Head of Fixed Income Outsourced Trading. Mr. Siegel will be based in New York and report to Michael Rosen and Jack Seibald, Global Co-Heads of Prime Brokerage and Outsourced Trading. Mr. Siegel brings more than 20 years of practice in credit markets to Cowen. Prior to joining Cowen, Mr. Siegel spent six years at Mitsubishi UFJ Financial Group in New York and London, where he most recently served as Managing Director, Head of Credit Americas and Global Credit Coordinator.공고 • Oct 01Cowen Grows Special Situations Group with Addition of Kenneth Garnett as Managing DirectorCowen Inc. announced that Kenneth Garnett has joined the firm’s Investment Banking team as a Managing Director in the Special Situations Group. Mr. Garnett will be based in New York and report to Lorie Beers, Cowen Managing Director and Head, Special Situations & Restructuring. He brings over two decades of experience in special situation private investing, restructuring investment banking and turnaround consulting. Mr. Garnett has spent over 20 years working in private equity investing, restructuring, investment banking and turnaround consulting. For the past six years, Mr. Garnett worked at Conway MacKenzie as Managing Director, Private Fund Services. Previously, he was a Partner and Founder at Renewal Capital, a private equity fund making special situations investments in the lower middle market, as well as a partner at investment bank Gordian Group.공고 • Sep 25+ 1 more updateClinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million.Clinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million on June 20, 2005. Under the terms of the agreement, each shareholder of 35.35 million outstanding Genaissance Pharmaceuticals, Inc.'s common stock will receive 0.065 shares of Clinical Data, Inc.'s common stock, each shareholder of 0.46 million outstanding Genaissance Pharmaceuticals, Inc.'s Series A preferred stock will receive 1.052326 shares of newly designated Clinical Data, Inc.'s Series A preferred stock, and Clinical Data, Inc. will also assume all existing Genaissance Pharmaceuticals, Inc.'s options. Xmark Asset Management, LLC agreed to sell its stake in the transaction. In the event of termination, Genaissance is required to pay Clinical Data a termination fee of $1.33 million. Upon completion of the acquisition, Kevin Rakin and Joseph Klein III of Genaissance Pharmaceuticals, Inc. will join Clinical Data, Inc.'s Board of Directors. The transaction is subject to shareholders' approval and has been unanimously approved by the Board. The transaction is expected to close by fourth quarter. WR Hambrecht + Co., LLC acted as financial advisor and John Hession, Marc Recht, Dr. Simona Levi-Minzi, Angelo Mignanelli, Revecca Schuster, Luke Albrecht, Jeff Wagner, Chip Kerby, Mark Collins, and Daphne Van de Meerssche of McDermott Will & Emery LLP acted as legal advisor to Clinical Data, Inc. CIBC World Markets Corp. acted as financial advisor and Steven D. Singer of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor to Genaissance Pharmaceuticals Inc. Michael A. Gordon of Sidley Austin Brown & Wood LLP acted as legal advisor to Ritchie Capital Management, LLC. Oppenheimer & Co. Inc. acted as financial advisor to Genaissance Pharmaceuticals, Inc.공고 • Sep 16Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for a consideration approximately $1.1 billion in cash.Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for approximately $1.1 billion in cash, on October 30, 2006. Under the terms of the agreement, Merck & Co. Inc. will pay $13 for each share of Sirna Therapeutics, for a total consideration of approximately $948.5 million in cash. Also, Merck & Co. Inc. will pay a consideration of approximately $57.6 million in cash, for all the outstanding options of Sirna Therapeutics as on June 30, 2006. Each option is valued at $10 with an exercise price of $3. Merck & Co. Inc. will pay a consideration of $127.30 million in cash, for all the outstanding warrants of Sirna Therapeutics as on December 31, 2005. Each warrant is valued at $10.93 with an exercise price of $2.07. If the agreement is cancelled, then Sirna Therapeutics will pay Merck & Co., Inc., a termination fee of $42.1 million. The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, approval by the stockholders of Sirna, resignations of the board of directors of Sirna, approval by governmental entities, consents of all third parties and other customary closing conditions. Sirna stockholders owning approximately 36% of Sirna's outstanding shares have committed to support the transaction and have entered into voting agreements. The board of directors of both Merck & Co. and Sirna has unanimously approved the agreement. The two companies expect to complete the acquisition in the first quarter of 2007. The termination fee was amended to $38 million. Goldman, Sachs & Co. was the financial advisor and Michael J. Kennedy and Sam Zucker from O’Melveny & Myers LLP were the legal advisors for Sirna Therapeutics Inc. David N. Shine and Brian T. Mangino from Fried, Frank, Harris, Shriver & Jacobson LLP were the legal advisors for Merck & Co., Inc. on the deal. Morgan Stanley was financial advisor for Merck. Latham & Watkins LLP was the legal advisor to Goldman, Sachs & Co. Morris, Nichols, Arsht & Tunnell LLP was legal advisor for Merck & Co. The Altman Group acted as information agent to Sirna and received $10,000 as fees. Sirna agreed to pay Goldman Sachs & Co. LLC an advisory fees of approximately $13.47 million of which $3.37 million payable upon announcement of the merger and $10.1 million payable on consummation of the merger.매출 및 비용 세부 내역Cowen가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:CWGR.P 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 221,27970771030 Sep 221,394122922030 Jun 221,428145918031 Mar 221,576176989031 Dec 211,9012891,190030 Sep 211,9853161,225030 Jun 211,8992981,167031 Mar 212,1003671,250031 Dec 201,566210984030 Sep 201,272123844030 Jun 201,183106814031 Mar 20838-2645031 Dec 1999018649030 Sep 1986918628030 Jun 1986829629031 Mar 1982529616031 Dec 1885536616030 Sep 18803-45604030 Jun 18772-56575031 Mar 18710-54546031 Dec 17585-68487030 Sep 175186451030 Jun 17460-1441031 Mar 17420-19387031 Dec 16410-26375030 Sep 163926378030 Jun 16390-1336031 Mar 16393183540양질의 수익: CWGR.P는 고품질 수익을 보유하고 있습니다.이익 마진 증가: CWGR.P의 현재 순 이익률 (5.4%)은 지난해 (15.2%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CWGR.P는 지난 5년 동안 흑자전환하며 연평균 49.5%의 수익 성장을 기록했습니다.성장 가속화: CWGR.P은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: CWGR.P은 지난 1년 동안 수익이 감소(-75.9%)하여 Capital Markets 업계 평균(34.4%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: CWGR.P의 자본 수익률(5%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/03/02 16:57종가2022/12/30 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cowen Inc.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Guy MoszkowskiBofA Global ResearchDevin RyanCitizens JMP Securities, LLCJames YaroGoldman Sachs5명의 분석가 더 보기
공고 • Feb 10Cowen Inc. to Report Q4, 2022 Results on Feb 17, 2023Cowen Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 17, 2023
공고 • Feb 10Cowen Inc. to Report Q4, 2022 Results on Feb 17, 2023Cowen Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 17, 2023
공고 • Jan 13Cowen Inc. Announces the Demise of Jack H. Nusbaum, DirectorCowen Inc. announced with great sadness that Director Jack H. Nusbaum passed away unexpectedly on January 11, 2021. Mr. Nusbaum has served as a member of Cowen’s Board since November 2009. He has been an advisor and friend to members of the Company’s leadership for over 30 years. Mr. Nusbaum was also a Senior Partner of the New York law firm of Willkie Farr & Gallagher LLP, serving as the firm’s Chairman from 1987 through 2009 and a partner in that firm for fifty years.
공고 • Jan 06Joram Siegel Joins Cowen as Head of Fixed Income Outsourced TradingCowen Inc. announced that Joram Siegel has joined its Outsourced Trading division as Managing Director, Head of Fixed Income Outsourced Trading. Mr. Siegel will be based in New York and report to Michael Rosen and Jack Seibald, Global Co-Heads of Prime Brokerage and Outsourced Trading. Mr. Siegel brings more than 20 years of practice in credit markets to Cowen. Prior to joining Cowen, Mr. Siegel spent six years at Mitsubishi UFJ Financial Group in New York and London, where he most recently served as Managing Director, Head of Credit Americas and Global Credit Coordinator.
공고 • Oct 01Cowen Grows Special Situations Group with Addition of Kenneth Garnett as Managing DirectorCowen Inc. announced that Kenneth Garnett has joined the firm’s Investment Banking team as a Managing Director in the Special Situations Group. Mr. Garnett will be based in New York and report to Lorie Beers, Cowen Managing Director and Head, Special Situations & Restructuring. He brings over two decades of experience in special situation private investing, restructuring investment banking and turnaround consulting. Mr. Garnett has spent over 20 years working in private equity investing, restructuring, investment banking and turnaround consulting. For the past six years, Mr. Garnett worked at Conway MacKenzie as Managing Director, Private Fund Services. Previously, he was a Partner and Founder at Renewal Capital, a private equity fund making special situations investments in the lower middle market, as well as a partner at investment bank Gordian Group.
공고 • Sep 25+ 1 more updateClinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million.Clinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million on June 20, 2005. Under the terms of the agreement, each shareholder of 35.35 million outstanding Genaissance Pharmaceuticals, Inc.'s common stock will receive 0.065 shares of Clinical Data, Inc.'s common stock, each shareholder of 0.46 million outstanding Genaissance Pharmaceuticals, Inc.'s Series A preferred stock will receive 1.052326 shares of newly designated Clinical Data, Inc.'s Series A preferred stock, and Clinical Data, Inc. will also assume all existing Genaissance Pharmaceuticals, Inc.'s options. Xmark Asset Management, LLC agreed to sell its stake in the transaction. In the event of termination, Genaissance is required to pay Clinical Data a termination fee of $1.33 million. Upon completion of the acquisition, Kevin Rakin and Joseph Klein III of Genaissance Pharmaceuticals, Inc. will join Clinical Data, Inc.'s Board of Directors. The transaction is subject to shareholders' approval and has been unanimously approved by the Board. The transaction is expected to close by fourth quarter. WR Hambrecht + Co., LLC acted as financial advisor and John Hession, Marc Recht, Dr. Simona Levi-Minzi, Angelo Mignanelli, Revecca Schuster, Luke Albrecht, Jeff Wagner, Chip Kerby, Mark Collins, and Daphne Van de Meerssche of McDermott Will & Emery LLP acted as legal advisor to Clinical Data, Inc. CIBC World Markets Corp. acted as financial advisor and Steven D. Singer of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor to Genaissance Pharmaceuticals Inc. Michael A. Gordon of Sidley Austin Brown & Wood LLP acted as legal advisor to Ritchie Capital Management, LLC. Oppenheimer & Co. Inc. acted as financial advisor to Genaissance Pharmaceuticals, Inc.
공고 • Sep 16Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for a consideration approximately $1.1 billion in cash.Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for approximately $1.1 billion in cash, on October 30, 2006. Under the terms of the agreement, Merck & Co. Inc. will pay $13 for each share of Sirna Therapeutics, for a total consideration of approximately $948.5 million in cash. Also, Merck & Co. Inc. will pay a consideration of approximately $57.6 million in cash, for all the outstanding options of Sirna Therapeutics as on June 30, 2006. Each option is valued at $10 with an exercise price of $3. Merck & Co. Inc. will pay a consideration of $127.30 million in cash, for all the outstanding warrants of Sirna Therapeutics as on December 31, 2005. Each warrant is valued at $10.93 with an exercise price of $2.07. If the agreement is cancelled, then Sirna Therapeutics will pay Merck & Co., Inc., a termination fee of $42.1 million. The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, approval by the stockholders of Sirna, resignations of the board of directors of Sirna, approval by governmental entities, consents of all third parties and other customary closing conditions. Sirna stockholders owning approximately 36% of Sirna's outstanding shares have committed to support the transaction and have entered into voting agreements. The board of directors of both Merck & Co. and Sirna has unanimously approved the agreement. The two companies expect to complete the acquisition in the first quarter of 2007. The termination fee was amended to $38 million. Goldman, Sachs & Co. was the financial advisor and Michael J. Kennedy and Sam Zucker from O’Melveny & Myers LLP were the legal advisors for Sirna Therapeutics Inc. David N. Shine and Brian T. Mangino from Fried, Frank, Harris, Shriver & Jacobson LLP were the legal advisors for Merck & Co., Inc. on the deal. Morgan Stanley was financial advisor for Merck. Latham & Watkins LLP was the legal advisor to Goldman, Sachs & Co. Morris, Nichols, Arsht & Tunnell LLP was legal advisor for Merck & Co. The Altman Group acted as information agent to Sirna and received $10,000 as fees. Sirna agreed to pay Goldman Sachs & Co. LLC an advisory fees of approximately $13.47 million of which $3.37 million payable upon announcement of the merger and $10.1 million payable on consummation of the merger.